Levetiracetam Desitin (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates synaptic transmission, decreasing abnormal neuronal firing and lowering the likelihood of seizure propagation throughout the central nervous system.

The dosage of levetiracetam is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate starting dose and any necessary adjustments during therapy.

Safety data for levetiracetam in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. It is often chosen for patients who require a medication with fewer hepatic metabolism concerns and a lower risk of pharmacokinetic interactions.

Levetiracetam tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture. Keep the product out of direct sunlight and away from excessive heat to maintain its stability and potency.

Levetiracetam Desitin is taken orally, usually with or without food, as a tablet that is swallowed whole with water. The exact administration schedule—once, twice, or three times daily—is determined by the prescribing physician based on therapeutic response.

Serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, significant mood changes including depression or suicidal thoughts, and rare blood disorders. Patients should be monitored closely for any signs of rash, mood alteration, or hematologic abnormalities.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with severe renal impairment who may require dose adjustments, and for those with a history of serious psychiatric disorders.